Jurgi Camblong Sells 8,500 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CEO Jurgi Camblong sold 8,500 shares of the firm’s stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $5.24, for a total value of $44,540.00. Following the transaction, the chief executive officer owned 3,620,995 shares in the company, valued at approximately $18,974,013.80. This trade represents a 0.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jurgi Camblong also recently made the following trade(s):

• On Monday, April 20th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.21, for a total value of $23,372.06.
• On Wednesday, April 15th, Jurgi Camblong sold 17,473 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.00, for a total value of $87,365.00.
• On Tuesday, April 14th, Jurgi Camblong sold 43,129 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.96, for a total value of $213,919.84.
• On Monday, April 13th, Jurgi Camblong sold 4,399 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.76, for a total value of $20,939.24.
• On Friday, April 10th, Jurgi Camblong sold 12,232 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.72, for a total value of $57,735.04.
• On Thursday, April 9th, Jurgi Camblong sold 1,950 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total value of $9,243.00.
• On Wednesday, April 8th, Jurgi Camblong sold 2,800 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.84, for a total value of $13,552.00.
• On Tuesday, April 7th, Jurgi Camblong sold 2,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.86, for a total value of $12,150.00.
• On Monday, April 6th, Jurgi Camblong sold 2,600 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.85, for a total value of $12,610.00.
• On Thursday, March 19th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.77, for a total value of $21,398.22.

SOPHiA GENETICS Trading Down 6.2%

Shares of SOPH opened at $4.88 on Friday. SOPHiA GENETICS SA has a 52-week low of $2.59 and a 52-week high of $5.70. The business’s fifty day moving average is $4.98 and its 200-day moving average is $4.89. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.90 and a current ratio of 2.06. The firm has a market cap of $334.23 million, a price-to-earnings ratio of -9.38 and a beta of 0.98.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. The business had revenue of $21.69 million during the quarter, compared to the consensus estimate of $20.40 million.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on SOPH shares. BTIG Research reiterated a “buy” rating and issued a $8.00 price target on shares of SOPHiA GENETICS in a research note on Wednesday, May 6th. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Tuesday, April 21st. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, SOPHiA GENETICS currently has a consensus rating of “Hold” and an average price target of $7.50.

Institutional Investors Weigh In On SOPHiA GENETICS

A number of hedge funds and other institutional investors have recently bought and sold shares of SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in SOPHiA GENETICS by 246.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after acquiring an additional 5,432,871 shares during the last quarter. Federated Hermes Inc. grew its position in SOPHiA GENETICS by 16.4% during the 2nd quarter. Federated Hermes Inc. now owns 220,000 shares of the company’s stock worth $682,000 after acquiring an additional 31,000 shares during the last quarter. Akre Capital Management LLC lifted its holdings in SOPHiA GENETICS by 66.2% during the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after buying an additional 1,481,636 shares during the period. Savvy Advisors Inc. acquired a new position in SOPHiA GENETICS during the 3rd quarter worth about $48,000. Finally, GSA Capital Partners LLP acquired a new position in SOPHiA GENETICS during the 3rd quarter worth about $59,000. Institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.